Logo

OpiCalc

FavoritesSpecialtiesDrugsGuidelinesMost Used

All Specialties

OpiCalc Logo
FavoritesSpecialtiesDrugsGuidelinesMost Used
FavesSpecsDrugsGuidesTop
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
OpiCalc Logo

OpiCalc

Easy, fast, and private medical tools for clinicians. Always free.

No Login Required
Ready for the Bedside

Resources

About UsEditorial PolicyMedical DisclaimerPrivacy PolicyTerms of UseCookie Policy

Support

Contact Us

Clinical Notice:OpiCalc is not a substitute for professional clinical judgment. Always verify dosages and guidelines.

OpiCalc © 2018-2026

•

All Rights Reserved

Registry Hub

Therapeutic Classification

gnrh agonist Registry

Clinical reference for gnrh agonist medications. Access safety monographs, dosing adjustments, and drug-drug interactions for all registered brand names and generics in this class.

Registered Medications (gnrh agonist)

This therapeutic registry is dynamically synthesized from professional clinical sources. Listing of a medication does not imply equivalence; refer to individual monographs for head-to-head pharmacological data.

MedicationTherapeutic ClassMaternal Safety

CAMCEVI ETM

Comprehensive clinical and safety monograph for CAMCEVI ETM (CAMCEVI ETM).

GnRH Agonist

caution

CAMCEVI KIT

Comprehensive clinical and safety monograph for CAMCEVI KIT (CAMCEVI KIT).

GnRH Agonist

caution

ELIGARD KIT

Comprehensive clinical and safety monograph for ELIGARD KIT (ELIGARD KIT).

GnRH Agonist Antineoplastic

caution

FACTREL

Comprehensive clinical and safety monograph for FACTREL (FACTREL).

GnRH Agonist

caution

FENSOLVI KIT

Comprehensive clinical and safety monograph for FENSOLVI KIT (FENSOLVI KIT).

GnRH Agonist

caution

LEUPROLIDE ACETATE

No significant drug interactions Causes an initial increase in testosterone levels which may worsen symptoms in prostate cancer patients.

GnRH Agonist

avoid

LEUPROLIDE ACETATE FOR DEPOT SUSPENSION

No significant drug interactions Causes an initial increase in testosterone levels which may worsen symptoms in prostate cancer patients.

GnRH Agonist

avoid

LUPRON

Comprehensive clinical and safety monograph for LUPRON (LUPRON).

GnRH Agonist

caution

LUPRON DEPOT

Comprehensive clinical and safety monograph for LUPRON DEPOT (LUPRON DEPOT).

GnRH Agonist

caution

LUPRON DEPOT-PED KIT

Comprehensive clinical and safety monograph for LUPRON DEPOT-PED KIT (LUPRON DEPOT-PED KIT).

GnRH Agonist

caution

LUTREPULSE KIT

Comprehensive clinical and safety monograph for LUTREPULSE KIT (LUTREPULSE KIT).

GnRH Agonist

caution

STIMUFEND

Comprehensive clinical and safety monograph for STIMUFEND (STIMUFEND).

GnRH Agonist

caution

SUPPRELIN

Comprehensive clinical and safety monograph for SUPPRELIN (SUPPRELIN).

GnRH Agonist

caution

SUPPRELIN LA

Comprehensive clinical and safety monograph for SUPPRELIN LA (SUPPRELIN LA).

GnRH Agonist

caution

SYNAREL

Comprehensive clinical and safety monograph for SYNAREL (SYNAREL).

GnRH Agonist

caution

TRELSTAR

Comprehensive clinical and safety monograph for TRELSTAR (TRELSTAR).

GnRH Agonist

caution

TRIPTODUR KIT

Comprehensive clinical and safety monograph for TRIPTODUR KIT (TRIPTODUR KIT).

GnRH Agonist

caution

VANTAS

Comprehensive clinical and safety monograph for VANTAS (VANTAS).

GnRH Agonist

caution

VIADUR

Comprehensive clinical and safety monograph for VIADUR (VIADUR).

GnRH Agonist

caution

ZOLADEX

Comprehensive clinical and safety monograph for ZOLADEX (ZOLADEX).

GnRH Agonist

caution